administering SNAP (recipient non-federal agencies).

Authority for Conducting the Matching Program

The authority for conducting the matching program is 42 U.S.C. 653(j)(10). State SNAP agencies are required to participate in the matching program, as provided by 7 U.S.C. 2020(e)(24).

Purpose(s)

The purpose of the matching program is to provide each participating state agency administering SNAP with new hire, quarterly wage, and unemployment insurance information from the OCSS NDNH system of records to assist them in establishing or verifying SNAP applicants' and recipients' eligibility for assistance, reducing payment errors, and maintaining program integrity, including determining whether duplicate participation exists or if the applicant or recipient resides in another state. The state SNAP agencies may also use the NDNH information for the secondary purpose of updating SNAP recipients' reported participation in work activities and updating the recipients' and their employers' contact information maintained by the state SNAP agencies.

Categories of Individuals

The categories of individuals whose data is used in the matching program are adult members of households who have applied for or receive SNAP benefits.

Categories of Records

The categories of records used in the matching program, which may include personal identifiers, are new hire, quarterly wage, and unemployment insurance information. The specific data elements that will be provided to OCSS in a state agency input file are:

- Submitting state code (two-digit Federal Information Processing Standard code)
- Date stamp (input file transmission date)
- Adult SNAP caseload month and year of adult SNAP applicants and recipients
- Adult SNAP applicant/recipient Social Security number
- Adult SNAP applicant/recipient's first, middle, and last name

The SNAP–NDNH Record Specifications offer optional programming for the state to customize matching. For example, states may use the Passback field to identify specific records in a file, use the same State Data Indicator field whether or not to receive NDNH data that was provided by the state, and notify OCSS whether or not to verify the name and Social Security number combinations in the state agency's input file using Social Security Administration processes, as states may undergo verification prior to sending the file to OCSS. The NDNH data elements that OCSS will return to the state agency are as follows:

a. New Hire File

- New hire processed date
- Employee name and address
- Employee date and state of hire
- Federal and state employer identification numbers
- Department of Defense code
- Employer name and address
- Transmitter agency code
- Transmitter state code
- Transmitter state or agency name

b. Quarterly Wage File

- Quarterly wage processed date
- Employee name
- Federal and state employer identification numbers
- Department of Defense code
- Employer name and address
- Employee wage amount
- Quarterly wage reporting period
- Transmitter agency code
- Transmitter state code
- Transmitter state or agency name

c. Unemployment Insurance File

- Unemployment insurance processed date
- Claimant name and address
- Claimant benefit amount
- Unemployment insurance reporting period
- Transmitter state code
- Transmitter state or agency name

System(s) of Records

The NDNH data used in this matching program will be disclosed from the following OCSS system of records, as authorized by routine use 15: *OCSS National Directory of New Hires, System No. 09–80–0381; see System of Records Notice (SORN) published in full at 89 FR 25625 (April 11, 2024).*

[FR Doc. 2024–10928 Filed 5–17–24; 8:45 am]

BILLING CODE 4184–42–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2022–N–2015]

Program Policy and Procedures Manual Guide 1240.3605 Regulating Animal Foods With Drug Claims; Withdrawal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of withdrawal.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing the withdrawal of the Center for Veterinary Medicine's (CVM's) Program Policy and Procedures Manual Guide (PPM) 1240.3605 Regulating Animal Foods with Drug Claims. This 1998 document presented guidance to CVM staff for the regulation of animal food that may have intended uses that result in the products also being drugs. FDA is withdrawing PPM 1240.3605 after determining that it no longer reflects Agency current thinking.

FOR FURTHER INFORMATION CONTACT: Kelly A. Louviere, Center for Veterinary Medicine (HFV–200), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–402–5815, *kelly.louviere@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: FDA is announcing the withdrawal of CVM's PPM 1240.3605 Regulating Animal Foods with Drug Claims. This 1998 document presented guidance to CVM staff for the regulation of animal food that may have intended uses that result in the products being drugs under section 201(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)).

In 2021, CVM initiated a review of PPM 1240.3605, spurred by stakeholder interest, including industry and government (*e.g.,* Congressional) stakeholders. Congress requested FDA ''review [PPM] 1240.3605 for solutions on how ingredient claims for animal production, animal well-being, food safety and the environment can be regulated as animal food.'' In making this request, Congress expressed concern that PPM 1240.3605 had not been updated since 1998 and had not kept pace with science (H. Rep. No. 117–82 at 91 (2022)).

On October 18, 2022, CVM held a virtual listening session to gather information and stakeholder feedback to be considered during our review of the regulation of animal food with certain types of claims, such as claims about environmental benefits (*e.g.,* reduced greenhouse gas emissions), production

(*e.g.,* growth promotion, feed efficiency), and effects on the animal microbiome. We specifically asked for feedback on how we could modernize or improve PPM 1240.3605, what challenges were presented by this PPM, and what additional types of claims or ingredients CVM should consider during its review of the policy. Many stakeholders requested that we update our PPM to provide for a larger set of ingredients that can be safely used in animal food to be treated other than as drugs and to encourage innovation that supports human and animal health, promotes sustainable animal production, and provides benefits to the environment.

After a thorough review of PPM 1240.3605, and careful consideration of stakeholder feedback, FDA has determined that PPM 1240.3605 no longer reflects Agency current thinking and is therefore withdrawing the PPM.

FDA encourages firms developing animal food, nutritional ingredients, or non-nutritive ingredients with intended uses that could make them a drug, including substances that are for use in animal food and are intended to affect the structure or any function of the animal's body, to contact the Agency early in the product development process. To contact FDA's Center for Veterinary Medicine about an animal food substance intended to have the effects described above, please email *animalfood-premarket@fda.hhs.gov.*

FDA intends to issue guidance to clarify our current thinking on the regulation of certain substances that are for use in animal food and are intended to affect the structure or any function of an animal's body.

Dated: May 14, 2024.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2024–10936 Filed 5–17–24; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; RFA–DK–23–004 Human Islet Research Network—Consortium on Modeling Autoimmune Diabetes (UG3/UH3).

Date: June 26, 2024.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, NIDDK, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Tori Stone, Ph.D., Scientific Review Officer, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, (301) 827–0994, *tori.stone@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: May 15, 2024.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–10992 Filed 5–17–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of K99/R00 Applications.

Date: June 24–25, 2024.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, National Institute of General Medical Sciences, Natcher Building, 45 Center Drive, Bethesda, Maryland 20892 (Virtual Meeting).

Contact Person: Tracy Koretsky, Ph.D., Scientific Review Officer, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, MSC 6200, Room 3AN12F, Bethesda, Maryland 20892, 301–594–2886, *tracy.koretsky@nih.gov.*

(Catalogue of Federal Domestic Assistance Program No. 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: May 15, 2024.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–10988 Filed 5–17–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Health Promotion in Communities Study Section.

Date: June 10–11, 2024.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Melrose Hotel, 2430 Pennsylvania Ave. NW, Washington, DC 20037 (In-Person Meeting).

Contact Person: Helena Eryam Dagadu, MPH, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3137, Bethesda, MD 20892, (301) 435–1266, *dagaduhe@csr.nih.gov.*

Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Community Influences on Health Behavior Study Section.

Date: June 11–12, 2024.